Factors influencing acute and late toxicity in the era of adjuvant hypofractionated breast radiotherapy

M. C. De Santis, F. Bonfantini, F. Di Salvo, M. Dispinzieri, E. Mantero, F. Soncini, P. Baili, M. Sant, G. Bianchi, C. Maggi, S. Di Cosimo, R. Agresti, E. Pignoli, R. Valdagni, L. Lozza

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose To evaluate toxicity in breast cancer patients treated with anthracycline and taxane based chemotherapy and whole breast hypofractionated radiotherapy, and to identify the risk factors for toxicity. Methods and materials 537 early breast cancer patients receiving hypofractionated radiotherapy after conservative surgery were enrolled from April 2009 to December 2014, in an Italian cancer institute. The dose was 42.4 Gy in 16 daily fractions, 2.65 Gy per fraction. The boost to the tumor bed was administered only in grade III breast cancer patients and in patients with close or positive margins. Acute and late toxicity were prospectively assessed during and after radiotherapy according to RTOG scale. The impact of patients clinical characteristics, performed treatments and dose inhomogeneities on the occurrence of an higher level of acute skin toxicity and late fibrosis has been evaluated by univariate and multivariate analysis. Results The mean age was 74 (range 46–91 yrs). 27% of patients received boost. 22% of cases (n = 119) received also chemotherapy. The median follow-up was 32 months. G1 and G2/G3 acute skin toxicity were 61.3% and 20.5% and G1 and G2/G3 late fibrosis 12.6% and 4.3% respectively. Chemotherapy (p = 0.04), diabetes (p = 0.04) and boost administration (p 

Original languageEnglish
Pages (from-to)90-95
Number of pages6
JournalBreast
Volume29
DOIs
Publication statusPublished - Oct 1 2016

Keywords

  • Breast cancer
  • Chemotherapy
  • Hypofractionated radiotherapy
  • RTOG scale
  • Toxicity

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Factors influencing acute and late toxicity in the era of adjuvant hypofractionated breast radiotherapy'. Together they form a unique fingerprint.

Cite this